{"id":107887,"date":"2025-03-13T08:12:00","date_gmt":"2025-03-13T11:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/vanotech-appoints-matthew-schiller-to-lead-business-development\/"},"modified":"2025-03-13T08:12:00","modified_gmt":"2025-03-13T11:12:00","slug":"vanotech-appoints-matthew-schiller-to-lead-business-development","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/vanotech-appoints-matthew-schiller-to-lead-business-development\/","title":{"rendered":"Vanotech Appoints Matthew Schiller to Lead Business Development"},"content":{"rendered":"

ROCKAWAY, N.J., March 13, 2025 (GLOBE NEWSWIRE) — Vanotech Ltd, a pharmaceutical company devoted to greatly improving the lives of people living with Ophthalmic, central nervous, digestive and endocrine conditions using innovative science that results in breakthrough medicines, announced today that Matthew Schiller has been appointed as Head of Business Development. Mr. Schiller\u00a0brings extensive leadership experience in biopharma business development and joins\u00a0Vanotech\u00a0to lead the Companys business development operations.<\/p>\n

Matts broad-based experience in strategic business development will be critical in driving the next phase of growth for Vanotech, said\u00a0Avner Ingerman, M.D., President and Chief Medical Officer of Vanotech. We are thrilled to welcome Matt to Vanotech and look forward to his leadership as we continue to advance our pipeline of transformative medicines.<\/p>\n

Mr. Schiller brings with him over two decades of biopharma business development experience with his most recent role serving as Head of Business Development at NexImmune, Inc. Prior to this role, Mr. Schiller worked at several private and public companies, including six years at Merck KGaA as Director of Global Licensing and Business Development for Immunology and Neurology.<\/p>\n

“I am excited to join Vanotech and contribute my expertise to advance cutting-edge therapies, said Mr. Schiller. I am honored to join a talented global team and look forward to collaborating with industry partners to bring better solutions to people in need.<\/p>\n

About Vanotech:<\/p>\n

Vanotech Ltd. is a US subsidiary of Chengdu Kanghong Pharmaceutical Group, which is publicly traded on the Shenzhen Stock Exchange (SHE) and headquartered in Sichuan Province, China. Founded in 1996, the company specializes in researching, developing, manufacturing, and distributing medicines targeting the Ophthalmic, central nervous, digestive, and endocrine systems. As one of Chinas leading pharmaceutical companies, Kanghong employs over 4000 people and operates in more than 12 countries and territories.
<\/em><\/p>\n

For more information please contact avner.ingerman@cnkh.com<\/em><\/p>\n

\"\"
\"\"<\/p>\n

A OESP<\/b> nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP<\/b> e sao de inteira responsabilidade da GlobeNewswire<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"ROCKAWAY, N.J., March 13, 2025 (GLOBE NEWSWIRE) — Vanotech Ltd, a pharmaceutical company devoted to greatly improving the lives of people living with Ophthalmic, central","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-107887","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/107887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=107887"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/107887\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=107887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=107887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=107887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}